IL15RA and B-cell non-Hodgkin lymphoma: The IL-15 superagonist/IL-15Rα-Fc fusion complex (designated ALT-803) has previously been shown to enhance NK lysis of tumor cells and to augment NK-cell ADCC of B cell lymphomas directed by rituximab [21, 22].